CHICAGO — Intravitreal triamcinolone and intravitreal dexamethasone sustained-release implant were both superior to periocular triamcinolone for the regional treatment of uveitic macular edema, according to a speaker here.
The multicenter, randomized POINT clinical trial included patients with macular edema with or without active uveitis randomly assigned to one of three treatment groups. Patients received 40 mg of periocular triamcinolone, 4 mg of intravitreal triamcinolone or Ozurdex (dexamethasone intravitreal implant 0.7 mg, Allergan). Researchers evaluated the primary outcome of
Uncategorized